Pyrroloquinoline Quinone (PQQ) for Aging
PQQ is biologically plausible and broadly recognized as safe, but the human evidence for slowing aging is too thin to support anti-aging claims: a single small, short pilot trial in a narrow population is not enough to conclude it works.
Why this grade7-layer evidence engine
This claim earns a weak, disputed grade because the entire human case rests on one underpowered study. A 6-week double-blind RCT in 34 elderly adults with mild cognitive impairment (PMID 38908296) reported modest gains, including a 14.4% rise in serum BDNF and small cognitive and cerebral-oxygenation improvements. But that trial was tiny, brief, ran in an MCI population rather than general aging, and carried an author conflict of interest with a supplement maker. No meta-analyses or systematic reviews on PQQ and aging endpoints exist.
The remaining support is animal data, which is consistent but cannot substitute for human outcomes. Mouse and cell studies show benefits across bone loss (PMID 37365714), muscle aging (PMID 38487591), immune aging (PMID 40192736), and suppression of the inflammatory senescence phenotype (PMID 40538098), converging on Nrf2 and mitochondrial pathways. However, much of this work is industry-funded, including studies tied to the PQQ patent holder (PMID 38487591) and a supplement company (PMID 40538098), and rodent anti-aging signals have repeatedly failed to translate to humans.
Regulators and clinicians reinforce the caution. FDA (GRAS), EFSA, and WHO-cited reviews deem PQQ safe up to about 20 mg/day in healthy adults, but these are safety clearances only, with no approved anti-aging or cognitive health claims, and pregnant or lactating women are excluded. Harvard Health states there is no proof such mitochondrial supplements slow aging, and the NIA warns that anti-aging supplement claims usually have little scientific backing. A drug-interaction flag (e.g., anticoagulants) adds further reason for restraint.
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditable▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.55
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 無高階證據可裁決
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 1 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status